© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Thyroid Cancers
FDA Approval Sought for Pralsetinib in RET+ Medullary Thyroid Cancer
July 01, 2020
"Pralsetinib has broad potential to address the medical needs of patients with RET-altered cancers, who have not traditionally benefited from targeted therapy even though their tumors have a known disease driver."
Encouraging Larotrectinib Data Underscores Importance of Genetic Testing in Metastatic Solid Tumors
June 18, 2020
In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the importance of conducting genetic testing on all patients with metastatic solid tumors following the exciting data on larotrectinib.
Genetic Testing Becomes Vital in Sequencing Treatments for Patients With Thyroid Cancer
June 10, 2020
In an interview with Targeted Oncology, Marcia Brose, MD, PhD, discussed the role of genetic testing in patients with thyroid cancer and the current treatment landscape.
Exploring Current Therapies for Thyroid Cancer With NTRK Mutations
June 10, 2020
Marcia Brose, MD, PhD, discusses the treatment options for patients with thyroid cancer and NTRK fusions.
Phase 2 Study Spurs Hope for Future Combination Trials in Anaplastic Thyroid Cancer
June 09, 2020
“Due to a lack of efficacy observed with lenvatinib monotherapy in anaplastic thyroid cancer, further investigation of lenvatinib in combination with a checkpoint inhibitor may be warranted rather than pursuing further lenvatinib as a single agent.”
Selpercatinib Prompts Dramatic Response in RET Fusion-Positive Anaplastic Thyroid Carcinoma
June 07, 2020
“In this case the detection of an expressed CCDC6-RET gene fusion in a tumor metastasis by RNA-based NGS suggested that RET inhibition might be an effective treatment option."
Treatments Improve PFS in Thyroid Cancer
May 28, 2020
Winston Tan, MD, discusses 2 agents that have advanced the treatment landscape for patients with thyroid cancer, including the multi-tyrosine kinase inhibitor lenvatinib and another TKI, sorafenib.
Targeted Therapy Plus Immunotherapy Combos Inspire Hope in Anaplastic Thyroid Cancer
May 28, 2020
In an interview with Targeted Oncology, Maria E. Cabanillas, MD, discussed the findings from a clinical trial evaluating potential atezolizumab combinations in patients with anaplastic thyroid cancer.
Spartalizumab Identified as New Treatment Prospect in Advanced Anaplastic Thyroid Cancer
May 12, 2020
"Targeting PD-1/PD-L1 may provide a much-needed treatment option for patients with PDL1–positive advanced ATC."
FDA Approves Selpercatinib for RET+ Lung and Thyroid Cancers
May 09, 2020
The FDA has approved selpercatinib capsules for the treatment of patients with lung cancer or thyroid cancer harboring RET alterations. This marks the first treatment approved to target RET gene alterations.